Dr Ajay Gopal of the Division of Medical Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, USA and colleagues have reported results from an international non-randomised phase II study of idelalisib monotherapy in patients with indolent non-Hodgkin's lymphoma. The overall response rate was impressive 57%, with a median progression-free survival of 11 months, values suggesting that the efficacy of idelalisib is similar or superior to those of other active treatment options in relapsed or refractory indolent non-Hodgkin's lymphoma. Read more
here.
No comments:
Post a Comment